Recent advances in the diagnosis and treatment of hypereosinophilic syndromes.
Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by marked peripheral blood and tissue eosinophilia resulting in end organ damage. Recent advances in molecular biology and immunology have led to the identification of a number of distinct subtypes of HES with differing epidemiology, pathogenesis, and prognosis. The ability to distinguish between these HES subtypes combined with the availability of new treatment modalities, including tyrosine kinase inhibitors and monoclonal antibodies, that target specific molecules involved in disease pathogenesis have dramatically altered the approach to the diagnosis and treatment of HES.
Klion
Amy D
AD
Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. aklion@mail.nih.gov
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004802:Eosinophilia / Q000175:diagnosis; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007438:Introns; D011379:Prognosis; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D013256:Steroids / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D013256:Steroids; D020796:Receptor, Platelet-Derived Growth Factor alpha